Lenvatinib mesylate

SKU: orb1298850

Description

Lenvatinib mesylate is an orally bioavailable, multi-targeted tyrosine kinase inhibitor that potently suppresses VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. It is widely used in preclinical in vitro and in vivo studies for investigating angiogenesis, tumor growth, and metastasis in various cancer models.

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 857890-39-2
• MW: 522.96
• Purity: 99.79% (May vary between batches)
• Formula: C₂₂H₂₃ClN₄O₇S
• SMILES: CS(O)(=O)=O.COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
• Target: PDGFR,FGFR,c-Kit,c-RET,VEGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.82 mM);DMSO:32.67 mg/mL (62.47 mM)

Bioactivity

• Target IC50:
  PDGFRα:51 nM|PDGFRβ:39 nM|c-Kit:100 nM|FGFR1:46 nM|VEGFR2:4 nM|VEGFR3:5.2 nM|VEGFR1:22 nM
• In Vitro:
  Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET). These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors.

Storage & Handling

• Storage: store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Vascular endothelial growth factor receptor, VEGFR, VEGFR1, VEGFR3, RET, SCFR, PDGFR, PDGFRα, PDGFRβ, Inhibitor, inhibit, Platelet-derived growth factor receptor, FGFR1, FGFR, Fibroblast growth factor receptor, E7080 (mesylate), E7080, E-7080, Lenvatinib, Lenvatinib mesylate, Lenvatinib Mesylate, CD117, c-Kit, cKit, cRET, E 7080

Compound Identifiers

PubChem CID

11237762